Metformin represents the first-line therapy in the management of type 2 diabetes for more than 60 years. Recent extensive studies, suggest that Metformin is much more than an antidiabetic drug. More specifically, Metformin has shown cardio and nephro-protective effects. A randomized controlled double-blinded trial called "Renomet", non-diabetic patients with early to moderate CKD will be treated with Metformin or placebo during 30 months in order to comparatively assess the evolution of their renal function. The aim of this study is therefore to determine whether treatment with metformin inhibits the decline of renal function better than treatment with a placebo. An attempt is made to align as closely as possible with the normal follow-up and examinations of a patient with kidney disease. In case of positive results, i.e. a significant delay of kidney function decline caused by Metformin, one may expect a net gain in the quality of life of CKD patients and major savings for the Belgian healthcare system.
| Title |
Metformin as RenoProtector in Non-Diabetic Patients with Progressive Chronic Kidney Disease (CKD stages 2, 3A and 3B): a multi-centre, practice-oriented, repurposing, double-blind, placebo-controlled, randomized clinical trial (RenoMet) |
|
Participants (P) |
Adult patients (≥18 years) of both gender, with chronic kidney disease (CKD stage 2, 3A or 3B, i. e. with estimated glomerular filtration rate (eGFR) between 30 and 90 ml/min/1.73m2), without and with proteinuria (<= 2.0 g/24hrs) and showing a decline of eGFR between 2.0 and 15.0 ml/min/year are eligible for inclusion. Patients will be recruited in one of the 14-16 participating Belgian renal care clinics where they have regular follow-up visits for their chronic renal failure. CKD patients with diabetes will be excluded. Also CKD patients with overt proteinuria (more than 2 g/24hrs) and patients showing a fast decline of renal function (more than 15 ml/min/year during the preceding two years) will be excluded. Additionally, all contraindications as per Glucophage SR SmPC including hypersensitivity to metformin and the respective tablet excipients will be considered as exclusion criteria |
|
Intervention (I) |
Metformin |
|
Control (C) |
Placebo |
|
Outcome (O) |
To demonstrate that a Metformin dose of 1000 mg/day, can effectively and safely slow the progression of renal failure in non-diabetic patients with chronic renal failure stages CKD 2, CKD3A and 3B |
|
Trial Design |
A multi-centre, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR ) in a new indication (renoprotection ) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B) |
|
Sample Size |
We plan to include 280 patients (140 in the metformin treatment group, 140 in the matched placebo control group) |
|
Trial duration |
42 months |
|
Budget |
€ 2 724 656,70 (VAT included) |
|
Sponsor |
University of Antwerpen |
|
Chief Investigator |
Prof. Dr. Marc De Broe University of Antwerpen |
|
Trial coordinator |
Monique Elseviers University of Antwerpen |
|
Sites - GPs |
16 sites |
|
External Partners |
Universitair Ziekenhuis Antwerpen (UZA) |
Investigator-led workstream 2017
